Findings

What do systematic reviews say?

78 questions · 94 findings · 5 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 35 · 37.2%GRADE not reported 2 · 2.1%Very low 39 · 41.5%Low 16 · 17%Moderate 2 · 2.1%High 0 · 0%

Metformin vs thiazolidinediones

Non‐fatal MI

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3020 participants
Very low

Metformin vs insulin

Serious adverse events

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs thiazolidinediones

Non‐fatal stroke

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 72 participants
Very low

Metformin vs thiazolidinediones

End‐stage renal disease

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs dipeptidyl‐peptidase 4 inhibitors

All‐cause mortality

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1977 participants
Very low

Metformin vs dipeptidyl‐peptidase 4 inhibitors

SAEs

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1977 participants
Very low

Metformin vs dipeptidyl‐peptidase 4 inhibitors

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs dipeptidyl‐peptidase 4 inhibitors

Cardiovascular mortality

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1206 participants
Very low

Metformin vs dipeptidyl‐peptidase 4 inhibitors

Non‐fatal MI

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 543 participants
Very low

Metformin vs dipeptidyl‐peptidase 4 inhibitors

Non‐fatal stroke

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 543 participants
Very low

Metformin vs dipeptidyl‐peptidase 4 inhibitors

End‐stage renal disease

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs glucagon like peptide‐1 analogues

All‐cause mortality

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs insulin

Quality of life Short‐Form 36 health survey (SF‐36)

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 91 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

SAEs

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs glucagon like peptide‐1 analogues

Cardiovascular mortality

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

Non‐fatal MI

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

Non‐fatal stroke

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

End‐stage renal disease

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found